Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling
Acute promyelocytic leukemia (APL) accounts for approximately 10–15% of newly diagnosed acute myeloid leukemia cases and presents with coagulopathy and bleeding. Prompt diagnosis and treatment are required to minimize early mortality in APL as initiation of all-trans retinoic acid therapy rapidly re...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/12/1595 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850239968385957888 |
|---|---|
| author | William Middlezong Victoria Stinnett Michael Phan Brian Phan Laura Morsberger Melanie Klausner Jen Ghabrial Natalie DeMetrick Jing Zhu Trisha James Aparna Pallavajjala Christopher D. Gocke Maria R. Baer Ying S. Zou |
| author_facet | William Middlezong Victoria Stinnett Michael Phan Brian Phan Laura Morsberger Melanie Klausner Jen Ghabrial Natalie DeMetrick Jing Zhu Trisha James Aparna Pallavajjala Christopher D. Gocke Maria R. Baer Ying S. Zou |
| author_sort | William Middlezong |
| collection | DOAJ |
| description | Acute promyelocytic leukemia (APL) accounts for approximately 10–15% of newly diagnosed acute myeloid leukemia cases and presents with coagulopathy and bleeding. Prompt diagnosis and treatment are required to minimize early mortality in APL as initiation of all-trans retinoic acid therapy rapidly reverses coagulopathy. The <i>PML::RARA</i> fusion is a hallmark of APL and its rapid identification is essential for rapid initiation of specific treatment to prevent early deaths from coagulopathy and bleeding and optimize patient outcomes. Given limitations and long turnaround time of current gene fusion diagnostic strategies, we have developed a novel amplification-free nanopore sequencing-based approach with low cost, easy setup, and fast turnaround time. We termed the approach CRISPR/Cas9-enriched nanopore sequencing with adaptive sampling (CENAS). Using CENAS, we successfully sequenced breakpoints of typical and atypical <i>PML::RARA</i> fusions in APL patients. Compared with the standard-of-care genetic diagnostic tests, CENAS achieved good concordance in detecting <i>PML::RARA</i> fusions in this study. CENAS allowed for the identification of sequence information of fusion breakpoints involved in typical and atypical <i>PML::RARA</i> fusions and identified additional genes (<i>ANKFN1</i> and <i>JOSD1</i>) and genomic regions (13q14.13) involving the atypical fusions. To the best of our knowledge, involvements of the <i>ANKFN1</i> gene, the <i>JOSD1</i> gene, and the 13q14.13 genomic region flanking with the <i>SIAH3</i> and <i>ZC3H13</i> genes have not been reported in the atypical <i>PML::RARA</i> fusions. CENAS has great potential to develop as a point-of-care test enabling immediate, low-cost bedside diagnosis of APL patients with a <i>PML::RARA</i> fusion. Given the early death rate in APL patients still reaches 15%, and ~10% of APL patients are resistant to initial therapy or prone to relapse, further sequencing studies of typical and atypical <i>PML::RARA</i> fusion might shed light on the pathophysiology of the disease and its responsiveness to treatment. Understanding the involvement of additional genes and positional effects related to the <i>PML</i> and <i>RARA</i> genes could shed light on their role in APL and may aid in the development of novel targeted therapies. |
| format | Article |
| id | doaj-art-e28610fe3e9e4fd6b412eecb1fca7cfe |
| institution | OA Journals |
| issn | 2218-273X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-e28610fe3e9e4fd6b412eecb1fca7cfe2025-08-20T02:01:00ZengMDPI AGBiomolecules2218-273X2024-12-011412159510.3390/biom14121595Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive SamplingWilliam Middlezong0Victoria Stinnett1Michael Phan2Brian Phan3Laura Morsberger4Melanie Klausner5Jen Ghabrial6Natalie DeMetrick7Jing Zhu8Trisha James9Aparna Pallavajjala10Christopher D. Gocke11Maria R. Baer12Ying S. Zou13Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USAKrieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USADepartment of Biology, The College of William and Mary, Williamsburg, VA 23186, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USADepartment of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USAAcute promyelocytic leukemia (APL) accounts for approximately 10–15% of newly diagnosed acute myeloid leukemia cases and presents with coagulopathy and bleeding. Prompt diagnosis and treatment are required to minimize early mortality in APL as initiation of all-trans retinoic acid therapy rapidly reverses coagulopathy. The <i>PML::RARA</i> fusion is a hallmark of APL and its rapid identification is essential for rapid initiation of specific treatment to prevent early deaths from coagulopathy and bleeding and optimize patient outcomes. Given limitations and long turnaround time of current gene fusion diagnostic strategies, we have developed a novel amplification-free nanopore sequencing-based approach with low cost, easy setup, and fast turnaround time. We termed the approach CRISPR/Cas9-enriched nanopore sequencing with adaptive sampling (CENAS). Using CENAS, we successfully sequenced breakpoints of typical and atypical <i>PML::RARA</i> fusions in APL patients. Compared with the standard-of-care genetic diagnostic tests, CENAS achieved good concordance in detecting <i>PML::RARA</i> fusions in this study. CENAS allowed for the identification of sequence information of fusion breakpoints involved in typical and atypical <i>PML::RARA</i> fusions and identified additional genes (<i>ANKFN1</i> and <i>JOSD1</i>) and genomic regions (13q14.13) involving the atypical fusions. To the best of our knowledge, involvements of the <i>ANKFN1</i> gene, the <i>JOSD1</i> gene, and the 13q14.13 genomic region flanking with the <i>SIAH3</i> and <i>ZC3H13</i> genes have not been reported in the atypical <i>PML::RARA</i> fusions. CENAS has great potential to develop as a point-of-care test enabling immediate, low-cost bedside diagnosis of APL patients with a <i>PML::RARA</i> fusion. Given the early death rate in APL patients still reaches 15%, and ~10% of APL patients are resistant to initial therapy or prone to relapse, further sequencing studies of typical and atypical <i>PML::RARA</i> fusion might shed light on the pathophysiology of the disease and its responsiveness to treatment. Understanding the involvement of additional genes and positional effects related to the <i>PML</i> and <i>RARA</i> genes could shed light on their role in APL and may aid in the development of novel targeted therapies.https://www.mdpi.com/2218-273X/14/12/1595CRISPR/Cas9nanopore sequencing<i>PML::RARA</i> fusionsacute promyelocytic leukemiaadaptive sampling |
| spellingShingle | William Middlezong Victoria Stinnett Michael Phan Brian Phan Laura Morsberger Melanie Klausner Jen Ghabrial Natalie DeMetrick Jing Zhu Trisha James Aparna Pallavajjala Christopher D. Gocke Maria R. Baer Ying S. Zou Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling Biomolecules CRISPR/Cas9 nanopore sequencing <i>PML::RARA</i> fusions acute promyelocytic leukemia adaptive sampling |
| title | Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling |
| title_full | Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling |
| title_fullStr | Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling |
| title_full_unstemmed | Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling |
| title_short | Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling |
| title_sort | rapid detection of i pml rara i fusions in acute promyelocytic leukemia crispr cas9 nanopore sequencing with adaptive sampling |
| topic | CRISPR/Cas9 nanopore sequencing <i>PML::RARA</i> fusions acute promyelocytic leukemia adaptive sampling |
| url | https://www.mdpi.com/2218-273X/14/12/1595 |
| work_keys_str_mv | AT williammiddlezong rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT victoriastinnett rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT michaelphan rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT brianphan rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT lauramorsberger rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT melanieklausner rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT jenghabrial rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT nataliedemetrick rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT jingzhu rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT trishajames rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT aparnapallavajjala rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT christopherdgocke rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT mariarbaer rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling AT yingszou rapiddetectionofipmlraraifusionsinacutepromyelocyticleukemiacrisprcas9nanoporesequencingwithadaptivesampling |